Molecular Sensing, Inc.

Molecular Sensing, Inc. (MSI) is commercializing Back-Scattering Interferometry (BSI), the world’s first label-free, conformation-sensitive detection technology for biophysical characterization of small molecule interactions with complex drug targets. This includes integral membrane proteins and biochemically intractable target binding assays in native-like, free-solution environments — no tags or tethering.